Skip to main content
Erschienen in: Supportive Care in Cancer 4/2017

18.11.2016 | Original Article

Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management

verfasst von: Kea Turner, Cleo A Samuel, Heidi AS Donovan, Ellen Beckjord, Alexandra Cardy, Mary Amanda Dew, GJ van Londen

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Providers’ communication skills play a key role in encouraging breast cancer survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine therapy (AET). The purpose of this study was to examine provider perspectives on patient-provider communication regarding AET symptom management and to explore whether provider perspectives vary across the multi-disciplinary team of providers involved in survivorship care.

Methods

We conducted three one-hour focus groups with a multi-disciplinary group of health care providers including oncology specialists, primary care physicians, and non-physician providers experienced in caring for breast cancer survivors undergoing AET (n = 13). Themes were organized using Epstein and Street’s (2007) Framework for Patient-Centered Communication in Cancer Care.

Results

The findings of this study suggest providers’ communication behaviors including managing survivors’ uncertainty, responding to survivors’ emotions, exchanging information, and enabling self-management influences the quality of patient-provider communication about AET symptoms. Additionally, lack of systematic symptom assessment tools for AET requires providers to use discretion in determining which symptoms to discuss with survivors resulting in approaches that vary based on providers’ discipline.

Conclusion

There may be AET-specific provider communication skills and behaviors that promote effective patient-provider communication but additional research is needed to identify practices and policies that encourage these skills and behaviors among the many providers involved in survivorship care. Efforts are also needed to coordinate AET symptom assessment across providers, clarify providers’ roles in symptom assessment, and determine best practices for AET symptom communication.
Literatur
1.
Zurück zum Zitat Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32(21):2255–2269. doi:10.1200/JCO.2013.54.2258 CrossRef Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32(21):2255–2269. doi:10.​1200/​JCO.​2013.​54.​2258 CrossRef
2.
Zurück zum Zitat Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60–62. doi:10.1016/S0140-6736(04)17666-6 CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60–62. doi:10.​1016/​S0140-6736(04)17666-6 CrossRefPubMed
3.
Zurück zum Zitat Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Study IE (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092. doi:10.1056/NEJMoa040331 CrossRefPubMed Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Study IE (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092. doi:10.​1056/​NEJMoa040331 CrossRefPubMed
4.
Zurück zum Zitat Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.​1016/​S0140-6736(05)66544-0 CrossRef
5.
Zurück zum Zitat Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(27):4120–4128. doi:10.1200/JCO.2009.25.9655 CrossRef Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(27):4120–4128. doi:10.​1200/​JCO.​2009.​25.​9655 CrossRef
7.
8.
Zurück zum Zitat Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(4):556–562. doi:10.1200/JCO.2007.11.5451 CrossRef Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(4):556–562. doi:10.​1200/​JCO.​2007.​11.​5451 CrossRef
9.
Zurück zum Zitat Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(4):549–555. doi:10.1200/JCO.2006.10.1022 CrossRef Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(4):549–555. doi:10.​1200/​JCO.​2006.​10.​1022 CrossRef
10.
Zurück zum Zitat Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(25):3877–3883. doi:10.1200/JCO.2007.10.7573 CrossRef Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(25):3877–3883. doi:10.​1200/​JCO.​2007.​10.​7573 CrossRef
13.
14.
Zurück zum Zitat Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059–2063. doi:10.1016/S0140-6736(00)03403-6 CrossRefPubMed Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059–2063. doi:10.​1016/​S0140-6736(00)03403-6 CrossRefPubMed
15.
Zurück zum Zitat Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(7):1154–1160. doi:10.1200/JCO.2009.23.4708 CrossRef Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(7):1154–1160. doi:10.​1200/​JCO.​2009.​23.​4708 CrossRef
16.
Zurück zum Zitat Paskett ED, Stark N (2000) Lymphedema: knowledge, treatment, and impact among breast cancer survivors. Breast J 6(6):373–378CrossRef Paskett ED, Stark N (2000) Lymphedema: knowledge, treatment, and impact among breast cancer survivors. Breast J 6(6):373–378CrossRef
17.
Zurück zum Zitat van Londen GJ, Donovan HS, Beckjord EB, Cardy AL, Bovbjerg DH, Davidson NE, Morse JQ, Switzer GE, Verdonck-de Leeuw IM, Dew MA (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668. doi:10.1188/14.ONF.660-668 CrossRefPubMedPubMedCentral van Londen GJ, Donovan HS, Beckjord EB, Cardy AL, Bovbjerg DH, Davidson NE, Morse JQ, Switzer GE, Verdonck-de Leeuw IM, Dew MA (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668. doi:10.​1188/​14.​ONF.​660-668 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Alfano CM, McGregor BA, Kuniyuki A, Reeve BB, Bowen DJ, Baumgartner KB, Bernstein L, Ballard-Barbash R, Malone KE, Ganz PA, McTiernan A (2006) Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psychooncology 15(11):985–1000. doi:10.1002/pon.1033 CrossRefPubMedPubMedCentral Alfano CM, McGregor BA, Kuniyuki A, Reeve BB, Bowen DJ, Baumgartner KB, Bernstein L, Ballard-Barbash R, Malone KE, Ganz PA, McTiernan A (2006) Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psychooncology 15(11):985–1000. doi:10.​1002/​pon.​1033 CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Chlebowski RT, McTiernan A (1999) Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 17(1):130–142CrossRef Chlebowski RT, McTiernan A (1999) Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 17(1):130–142CrossRef
21.
Zurück zum Zitat Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang YT, Silliman RA, Weeks JC, Mandelblatt JS (2002) Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol Off J Am Soc Clin Oncol 20(4):1008–1016CrossRef Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang YT, Silliman RA, Weeks JC, Mandelblatt JS (2002) Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol Off J Am Soc Clin Oncol 20(4):1008–1016CrossRef
22.
Zurück zum Zitat Ong LM, Visser MR, Lammes FB, de Haes JC (2000) Doctor-patient communication and cancer patients' quality of life and satisfaction. Patient Educ Couns 41(2):145–156CrossRef Ong LM, Visser MR, Lammes FB, de Haes JC (2000) Doctor-patient communication and cancer patients' quality of life and satisfaction. Patient Educ Couns 41(2):145–156CrossRef
24.
25.
Zurück zum Zitat Hewitt M, Greenfield S, Stovall E (2005) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington DC Hewitt M, Greenfield S, Stovall E (2005) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington DC
28.
Zurück zum Zitat Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(Suppl 2):S459–S466. doi:10.1007/s11606-009-1000-2 CrossRefPubMed Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(Suppl 2):S459–S466. doi:10.​1007/​s11606-009-1000-2 CrossRefPubMed
30.
Zurück zum Zitat Epstein RM, Street RLJ (2007) Patient-centered communication in cancer care: promoting healing and reducing suffering. National Cancer Institute, Bethesda, MD Epstein RM, Street RLJ (2007) Patient-centered communication in cancer care: promoting healing and reducing suffering. National Cancer Institute, Bethesda, MD
31.
Zurück zum Zitat Taylor B (2013) Qualitative research in the health sciences. Routledge, New YorkCrossRef Taylor B (2013) Qualitative research in the health sciences. Routledge, New YorkCrossRef
32.
Zurück zum Zitat Golant M, Altman T, Martin C (2003) Managing cancer side effects to improve quality of life: a cancer psychoeducation program. Cancer Nurs 26(1):37–44 quiz 45-36CrossRef Golant M, Altman T, Martin C (2003) Managing cancer side effects to improve quality of life: a cancer psychoeducation program. Cancer Nurs 26(1):37–44 quiz 45-36CrossRef
33.
Zurück zum Zitat Osse BH, Vernooij-Dassen MJ, Schadé E, de Vree B, van den Muijsenbergh ME, Grol RP (2002) Problems to discuss with cancer patients in palliative care: a comprehensive approach. Patient Educ Couns 47(3):195–204CrossRef Osse BH, Vernooij-Dassen MJ, Schadé E, de Vree B, van den Muijsenbergh ME, Grol RP (2002) Problems to discuss with cancer patients in palliative care: a comprehensive approach. Patient Educ Couns 47(3):195–204CrossRef
34.
Zurück zum Zitat Canivet D, Delvaux N, Gibon AS, Brancart C, Slachmuylder JL, Razavi D (2014) Improving communication in cancer pain management nursing: a randomized controlled study assessing the efficacy of a communication skills training program. Support Care Cancer 22(12):3311–3320. doi:10.1007/s00520-014-2357-2 CrossRefPubMed Canivet D, Delvaux N, Gibon AS, Brancart C, Slachmuylder JL, Razavi D (2014) Improving communication in cancer pain management nursing: a randomized controlled study assessing the efficacy of a communication skills training program. Support Care Cancer 22(12):3311–3320. doi:10.​1007/​s00520-014-2357-2 CrossRefPubMed
35.
Zurück zum Zitat Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128(2):553–561. doi:10.1007/s10549-011-1378-5 CrossRefPubMed Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128(2):553–561. doi:10.​1007/​s10549-011-1378-5 CrossRefPubMed
36.
Zurück zum Zitat Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B (2009) Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 76(2):142–148. doi:10.1159/000195540 CrossRefPubMed Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B (2009) Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 76(2):142–148. doi:10.​1159/​000195540 CrossRefPubMed
38.
39.
Zurück zum Zitat Johnson RL, Roter D, Powe NR, Cooper LA (2004) Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health 94(12):2084–2090CrossRef Johnson RL, Roter D, Powe NR, Cooper LA (2004) Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health 94(12):2084–2090CrossRef
40.
Zurück zum Zitat Cooper-Patrick L, Gallo JJ, Gonzales JJ, Vu HT, Powe NR, Nelson C, Ford DE (1999) Race, gender, and partnership in the patient-physician relationship. JAMA 282(6):583–589CrossRef Cooper-Patrick L, Gallo JJ, Gonzales JJ, Vu HT, Powe NR, Nelson C, Ford DE (1999) Race, gender, and partnership in the patient-physician relationship. JAMA 282(6):583–589CrossRef
Metadaten
Titel
Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management
verfasst von
Kea Turner
Cleo A Samuel
Heidi AS Donovan
Ellen Beckjord
Alexandra Cardy
Mary Amanda Dew
GJ van Londen
Publikationsdatum
18.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3491-9

Weitere Artikel der Ausgabe 4/2017

Supportive Care in Cancer 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.